Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07317778CT.gov Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07041437CT.gov Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06842472CT.gov PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06470672CT.gov Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06500208CT.gov Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | — | Recruiting | — | — | — |
NCT06592625CT.gov Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients | — | Not Yet Recruiting | — | — | — |
NCT06470633CT.gov To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06433609CT.gov Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06411457CT.gov SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer | — | Unknown | — | — | — |
NCT06254066CT.gov Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer | — | Not Yet Recruiting | — | — | — |
Show 4 more trialsShow fewer
NCT06229067CT.gov Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06149130CT.gov Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT06165900CT.gov Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC | — | Recruiting | — | — | — |
NCT05353361CT.gov A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2 | CC · 43 |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Vitamin D | University of Illinois at Chicago | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Adriamycin | George Washington University | P4 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Peg-Rhg-Csf | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →